drugset / Trial / NCT02250157

A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies

NCT02250157

Phase 1 Completed 35 enrolled Athenex, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study a nonrandomized, open-label, uncontrolled, single group assignment, safety and activity study in subjects with histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.

Timeline

Start
2014-09-05
Primary completion
2020-03-04
Completion
2020-03-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule Oral
Background HM30181AK Unknown Oral

Indications